Inhaltsverzeichnis
News
08.09.2022 Save the date: GBG-Jahrestreffen 2023
Das GBG-Jahrestreffen 2023 findet am 2.&3. März 2023 in Frankfurt statt.
Mehr ...02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
Mehr ...03.08.2022 GBG-Research at EMSO 2022
We are proud to present our research at ESMO Congress 2022 in Paris.
Mehr ...31.07.2022 July 2022: HER2-positive breast cancer patients with brain metastases have the best prognosis compared to other tumor subtypes
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
Mehr ...14.07.2022 Eight-year data from APHINITY study presented
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
Mehr ...